A clinical study of lyophilized intravenous human immunoglobulin containing high-titer cytomegalovirus-neutralizing antibody for the treatment of cytomegalovirus viremia after allogeneic hematopoietic stem cell transplantation | Zendy

Ping Zhang | Zendy; Donglin Yang | Zendy; Jixin Tian | Zendy; Sizhou Feng | Zendy; Erlie Jiang | Zendy; Mingzhe Han | Zendy

Open Access

A clinical study of lyophilized intravenous human immunoglobulin containing high-titer cytomegalovirus-neutralizing antibody for the treatment of cytomegalovirus viremia after allogeneic hematopoietic stem cell transplantation

Author(s) -

Ping Zhang,

Donglin Yang,

Jixin Tian,

Sizhou Feng,

Erlie Jiang,

Mingzhe Han

Publication year - 2021

Publication title -

annals of palliative medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.546

H-Index - 19

eISSN - 2224-5839

pISSN - 2224-5820

DOI - 10.21037/apm-21-1069

Subject(s) - medicine , viremia , cytomegalovirus , antibody , titer , hematopoietic stem cell transplantation , virology , immunology , transplantation , neutralizing antibody , stem cell , virus , viral disease , herpesviridae , biology , genetics

Cytomegalovirus (CMV) infection increases the risk of death after allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, some patients do not respond to ganciclovir (GCV) or foscarnet sodium. Lyophilized intravenous human immunoglobulin containing high-titer CMV-neutralizing antibody (CMV-IVIG) is another option to further improve treatment safety and efficacy. This study was designed to evaluate the efficacy of the combination of CMV-IVIG with traditional antiviral drugs (GCV or foscarnet sodium) at different time points for the treatment of post-allo-HSCT CMV viremia and to determine the clinical value of CMV-IVIG as a preemptive treatment strategy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research